← All drugs
Drug · FAERS side-effect profile with label screen

Sodium Chloride side effects: what 78,465 FDA adverse event reports show

Sodium Chloride · 1,234 reaction terms · 323,633 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

78,465 reports · 80% serious · 6,827 with death outcome · 59% female

openFDA FAERS counts, all years, deduplication not applied

Used for

14.6% Sodium Chloride Injection, USP Additive Solution is indicated for parenteral restoration of sodium ion in patients with restricted oral intake. Sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome. 14.6% Sodium Chloride Additive Solution may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes.

FDA label, Indications and Usage

What it is

DESCRIPTION 14.6% Sodium Chloride Injection, USP Additive Solution is a sterile, nonpyrogenic, concentrated solution for intravenous administration ONLY AFTER DILUTION to replenish electrolytes.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Reporting / coding artifact 4Lab value / disease marker 3Not in label — unassessed 33
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,194 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vaginal flatulence119170.7
135.5–215.0ROR 170.9 · calibrated p 2e-9 ✓
102.2 EB05 87.7 · IC025 +5.9
3/3 methods agree
Not in label — unassessedserious n=119 · ♀ 100% (drug 59%)no trial arm names this drug
Device wireless communication issue80125.7
96.3–164.1ROR 125.9 · calibrated p 3e-8 ✓
83.7 EB05 69.4 · IC025 +5.4
3/3 methods agree
Reporting / coding artifact100% consumerno trial arm names this drug
Deafness permanent56105.7
77.6–144.2ROR 105.8 · calibrated p 1e-7 ✓
73.8 EB05 59.0 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=56no trial arm names this drug
Device maintenance issue12072.1
58.9–88.2ROR 72.2 · calibrated p 1e-6 ✓
56.3 EB05 48.3 · IC025 +5.2
3/3 methods agree
Reporting / coding artifactserious n=47 · 100% consumerno trial arm names this drug
Infusion site discharge30056.7
50.1–64.3ROR 56.9 · calibrated p 6e-6 ✓
46.7 EB05 42.4 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=182 · 87% consumerno trial arm names this drug
Wound infection pseudomonas5354.6
40.6–73.3ROR 54.6 · calibrated p 1e-5 ✓
44.7 EB05 35.5 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=53 · ♀ 100% (drug 59%) · 100% clinicianno trial arm names this drug
Granulocyte count decreased29853.5
47.3–60.6ROR 53.7 · calibrated p 9e-6 ✓
44.5 EB05 40.4 · IC025 +5.2
3/3 methods agree
Lab value / disease markerserious n=298no trial arm names this drug
Myelosuppression5,18047.9
46.5–49.3ROR 51.2 · calibrated p 1e-5 ✓
40.6 EB05 39.7 · IC025 +5.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 42.1 · serious PRR 29.3 · 92% clinicianno trial arm names this drug
Infective pulmonary exacerbation of cystic fibrosis79645.3
42.0–48.8ROR 45.7 · calibrated p 2e-5 ✓
38.7 EB05 36.5 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=727no trial arm names this drug
Ejection fraction7841.0
32.3–52.1ROR 41.1 · calibrated p 6e-5 ✓
35.3 EB05 29.2 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=78 · ♀ 100% (drug 59%)no trial arm names this drug
Cystic fibrosis respiratory infection suppression11940.6
33.5–49.3ROR 40.7 · calibrated p 5e-5 ✓
35.1 EB05 30.1 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=119 · 100% consumerno trial arm names this drug
Osmotic demyelination syndrome9740.2
32.5–49.8ROR 40.3 · calibrated p 6e-5 ✓
34.8 EB05 29.4 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=97 · 100% clinicianno trial arm names this drug
Sensitisation9939.6
32.0–48.9ROR 39.6 · calibrated p 7e-5 ✓
34.3 EB05 29.0 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=99 · ♀ 100% (drug 59%)no trial arm names this drug
Device infusion issue29436.3
32.2–41.0ROR 36.5 · calibrated p 9e-5 ✓
32.0 EB05 29.0 · IC025 +4.7
3/3 methods agree
Reporting / coding artifactserious n=169 · 80% consumerno trial arm names this drug
Infusion site haemorrhage37635.0
31.4–38.9ROR 35.1 · calibrated p 1e-4 ✓
30.9 EB05 28.4 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=192 · 81% consumerno trial arm names this drug
Infusion site irritation14033.8
28.4–40.3ROR 33.9 · calibrated p 2e-4 ✓
30.0 EB05 26.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=52 · ♀ 82% (drug 59%) · 100% consumerno trial arm names this drug
Endocrine ophthalmopathy9032.5
26.1–40.5ROR 32.6 · calibrated p 2e-4 ✓
28.9 EB05 24.2 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=90no trial arm names this drug
Infusion site discomfort10931.8
26.1–38.8ROR 31.8 · calibrated p 2e-4 ✓
28.3 EB05 24.1 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=61 · 100% consumerno trial arm names this drug
Interleukin level increased5329.3
22.1–39.0ROR 29.4 · calibrated p 4e-4 ✓
26.3 EB05 20.9 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=53 · ♀ 0% (drug 59%) · 100% clinicianno trial arm names this drug
Cystic fibrosis53828.5
26.1–31.2ROR 28.7 · calibrated p 3e-4 ✓
25.8 EB05 24.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=521no trial arm names this drug
Acidosis hyperchloraemic5628.0
21.3–36.9ROR 28.0 · calibrated p 5e-4 ✓
25.2 EB05 20.1 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=55 · ♀ 0% (drug 59%) · 100% clinicianno trial arm names this drug
Infusion site induration13427.7
23.2–33.1ROR 27.8 · calibrated p 4e-4 ✓
25.1 EB05 21.7 · IC025 +4.2
3/3 methods agree
Not in label — unassessed♀ 81% (drug 59%) · 100% consumerno trial arm names this drug
Infusion site mass9927.2
22.1–33.5ROR 27.2 · calibrated p 5e-4 ✓
24.6 EB05 20.8 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=56 · ♀ 100% (drug 59%) · 100% consumerno trial arm names this drug
Infusion site discolouration7926.9
21.3–33.9ROR 26.9 · calibrated p 5e-4 ✓
24.4 EB05 20.2 · IC025 +4.0
3/3 methods agree
Not in label — unassessed♀ 100% (drug 59%) · 100% consumerno trial arm names this drug
Infusion site swelling55726.5
24.3–28.9ROR 26.7 · calibrated p 5e-4 ✓
24.1 EB05 22.5 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=271 · 76% consumerno trial arm names this drug
Infusion site inflammation6126.5
20.3–34.4ROR 26.5 · calibrated p 6e-4 ✓
24.0 EB05 19.3 · IC025 +3.9
3/3 methods agree
Not in label — unassessed100% consumerno trial arm names this drug
Infusion site pain1,15326.4
24.9–28.1ROR 26.8 · calibrated p 5e-4 ✓
24.1 EB05 23.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 16.5 · serious n=498 · 79% consumerno trial arm names this drug
Infusion site warmth10625.7
21.1–31.4ROR 25.8 · calibrated p 6e-4 ✓
23.4 EB05 19.9 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=46 · 100% consumerno trial arm names this drug
Infusion site erythema71225.0
23.2–27.0ROR 25.2 · calibrated p 7e-4 ✓
22.9 EB05 21.5 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=331 · 80% consumerno trial arm names this drug
Infusion site pruritus26224.4
21.5–27.7ROR 24.5 · calibrated p 8e-4 ✓
22.4 EB05 20.2 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=160 · ♀ 80% (drug 59%) · 79% consumerno trial arm names this drug
Infusion site infection18523.7
20.4–27.5ROR 23.7 · calibrated p 9e-4 ✓
21.7 EB05 19.2 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=87 · ♀ 81% (drug 59%) · 82% consumerno trial arm names this drug
Infusion site bruising16822.8
19.5–26.7ROR 22.9 · calibrated p 0.001 ✓
21.0 EB05 18.5 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=116 · ♀ 80% (drug 59%)no trial arm names this drug
Hereditary angioedema81722.5
20.9–24.1ROR 22.7 · calibrated p 0.001 ✓
20.8 EB05 19.6 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious PRR 15.9 · ♀ 85% (drug 59%)no trial arm names this drug
Infusion site rash10522.2
18.2–27.1ROR 22.3 · calibrated p 0.001 ✓
20.5 EB05 17.4 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=68no trial arm names this drug
Female genital tract fistula12921.6
18.0–25.8ROR 21.6 · calibrated p 0.001 ✓
20.0 EB05 17.2 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=128 · ♀ 100% (drug 59%)no trial arm names this drug
Incorrect product formulation administered6321.5
16.7–27.8ROR 21.5 · calibrated p 0.002 ✓
19.9 EB05 16.1 · IC025 +3.7
3/3 methods agree
Reporting / coding artifact♀ 100% (drug 59%) · 100% consumerno trial arm names this drug
Blood fibrinogen decreased7519.1
15.1–24.1ROR 19.1 · calibrated p 0.003 ✓
17.8 EB05 14.6 · IC025 +3.6
3/3 methods agree
Lab value / disease markerserious n=75no trial arm names this drug
Chronic sinusitis24918.9
16.7–21.5ROR 19.0 · calibrated p 0.003 ✓
17.7 EB05 15.9 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=242 · ♀ 100% (drug 59%)no trial arm names this drug
Catheter site swelling5817.9
13.7–23.4ROR 17.9 · calibrated p 0.004 ✓
16.7 EB05 13.4 · IC025 +3.5
3/3 methods agree
Not in label — unassessed100% consumerno trial arm names this drug
Polycystic ovaries9817.7
14.4–21.7ROR 17.7 · calibrated p 0.004 ✓
16.6 EB05 14.0 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=98 · ♀ 100% (drug 59%)no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Hyponatraemia1,5135.14.8–5.4signal
Neutropenia / agranulocytosis3,5933.93.8–4.0signal
Thrombocytopenia2,2252.72.6–2.8signal
Serious infection7,7342.72.6–2.7signal
Liver injury2,5122.22.1–2.3signal
Anaemia2,4572.22.1–2.3signal
Anaphylaxis / angioedema1,0112.22.0–2.3signal
Kidney injury3,1501.81.8–1.9raised
Gi bleeding1,1181.61.5–1.7raised
Arrhythmia / qt1,1821.61.5–1.7raised
Severe cutaneous reaction4471.61.5–1.8raised
Interstitial lung disease5621.61.4–1.7raised
Opportunistic infection7911.61.4–1.7raised
Venous thromboembolism1,2191.51.4–1.6raised
Fall / fracture2,1171.51.4–1.6raised
Seizure1,0631.41.4–1.5raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Sodium Chloride only as a background or rescue medication (NCT05127434, NCT04516746); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Nausea5,6281.9
1.9–2.0ROR 2.0 · calibrated p 0.934
1.9 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.8 · serious PRR 2.2no trial arm names this drug
Myelosuppression5,18047.9
46.5–49.3ROR 51.2 · calibrated p 1e-5 ✓
40.6 EB05 39.7 · IC025 +5.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 42.1 · serious PRR 29.3 · 92% clinicianno trial arm names this drug
Dyspnoea (shortness of breath)4,9572.4
2.3–2.4ROR 2.4 · calibrated p 0.838
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.1 · serious PRR 2.0no trial arm names this drug
Off label use (used outside approved label)4,9291.5
1.5–1.6ROR 1.6 · calibrated p 0.677
1.5 EB05 1.5 · IC025 +0.6Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Headache4,4961.9
1.9–2.0ROR 2.0 · calibrated p 0.933
1.9 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.9no trial arm names this drug
Pyrexia (fever)4,3893.4
3.3–3.5ROR 3.6 · calibrated p 0.470
3.4 EB05 3.3 · IC025 +1.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.0 · serious PRR 2.7no trial arm names this drug
Fatigue (tiredness)4,3121.5
1.4–1.5ROR 1.5 · calibrated p 0.650
1.5 EB05 1.4 · IC025 +0.5Not in label — unassessedage-adj. PRR 1.3 · serious PRR 1.5no trial arm names this drug
Vomiting3,9912.3
2.2–2.4ROR 2.4 · calibrated p 0.878
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.1 · serious PRR 2.1no trial arm names this drug
Diarrhoea (diarrhea)3,8531.6
1.6–1.7ROR 1.6 · calibrated p 0.728
1.6 EB05 1.6 · IC025 +0.6Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.6no trial arm names this drug
Pneumonia (lung infection)3,5352.9
2.8–3.0ROR 3.0 · calibrated p 0.616
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.5 · serious PRR 2.2no trial arm names this drug
Pain3,1511.4
1.3–1.4ROR 1.4 · calibrated p 0.565
1.4 EB05 1.3 · IC025 +0.4Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.2no trial arm names this drug
White blood cell count decreased2,8867.3
7.0–7.5ROR 7.5 · calibrated p 0.080
7.1 EB05 6.9 · IC025 +2.8
3/3 methods agree
Lab value / disease markerage-adj. PRR 7.6 · serious PRR 7.1no trial arm names this drug
Drug ineffective (drug did not work)2,7890.6
0.5–0.6ROR 0.5 · calibrated p 0.065
0.6 EB05 0.5 · IC025 -0.9
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.6 · serious PRR 1.0no trial arm names this drug
Cough2,7062.6
2.5–2.7ROR 2.7 · calibrated p 0.750
2.6 EB05 2.5 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.1 · serious PRR 2.5no trial arm names this drug
Dizziness2,6351.4
1.4–1.5ROR 1.4 · calibrated p 0.595
1.4 EB05 1.4 · IC025 +0.4Not in label — unassessedage-adj. PRR 1.3 · serious PRR 1.4no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Methotrexate Sodium ↔ Rheumatoid Arthritis.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Sodium Chloride?

In FDA FAERS, the most frequently co-reported reaction terms for Sodium Chloride are nausea, myelosuppression, dyspnoea, headache, pyrexia, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Sodium Chloride have an FDA boxed warning?

No. The FDA label retrieved for Sodium Chloride has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Sodium Chloride causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.